echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Genes and obesity drive diabetes epidemic in China

    Genes and obesity drive diabetes epidemic in China

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The study was carried out by Professor Wang Weiqing of Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine, and many well-known professors in China who study diabetesNing Guang, a member of the Chinese Academy of Engineering, believes that the study reveals the grim reality of diabetes in China, and brings light to the prevention and treatment of diabetesprevious lying that beta cell dysfunction is the main pathogenesis of type 2 diabetes ChineseBut beta cell dysfunction is not enough to explain the rapid increase in diabetes prevalence over the past 40 yearsWith the evolution of the lifestyle of our country, the prevalence of obesity and type 2 diabetes is on the rise in parallelSo, does obesity affect the epidemic of diabetes in China? What is the connection between the two?the study covered 94,952 people aged 40 and overStudies have confirmed that insulin resistance affected by obesity is a more important risk factor for diabetes in China than beta cell dysfunctionThe findings of the study correct the international concept of the cause of diabetes in China, and also make the industry's understanding of the prevalence and potential causes of diabetes in China more clearProfessor Weiqing Wang, apaper, points out that weaker beta cell function, along with higher obesity rates and accompanying insulin resistance, add extra blows to the function of otherwise fragile beta cells, leading to a continued increase in diabetes prevalenceIn the future diabetes prevention, we should advocate early intervention strategies to reduce the functional burden of beta cells, and in treatment, emphasis should be placed on combined treatment for insulin resistance and beta cell dysfunction, increasing insulin promoters while improving insulin resistance, and replenishing insulin in a timely manner.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.